Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes

被引:23
|
作者
Snoeck, J
Riva, C
Steegen, K
Schrooten, Y
Maes, B
Vergne, L
Van Laethem, K
Peeters, M
Vandamme, AM
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[2] Univ Milan, Inst Infect & Trop Dis, Milan, Italy
[3] Univ Hosp Montpellier, Dept Virol, Montpellier, France
[4] Univ Hosp Montpellier, Dept Infect Dis, Montpellier, France
[5] Inst Rech & Dev, Retrovirus Lab, UR036, Montpellier, France
[6] Katholieke Univ Leuven Hosp, AID Reference Lab, Louvain, Belgium
关键词
genotypic assay; RNase H region; non-B subtypes; gag cleavage sites;
D O I
10.1016/j.jviromet.2005.04.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Genotypic assays are used often to guide clinicians in decisions concerning the treatment of patients. An optimized sequence-based genotypic assay was used to determine the whole protease and reverse transcriptase (RT) gene, including the gag cleavage site region and RNase H region. Since non-B subtypes are increasing in countries where subtype B was the most prevalent Subtype, and treatment becomes more available in developing countries where the epidemic is characterized by a high prevalence of non-B subtypes, it was important that the genotypic test was evaluated using a panel of different subtypes. Amplification was successful for different subtypes: A, B, C, D, F, G, H, J, CRF01_AE, CRF02-AG, CRF11-cpx, CRF13-cpx and an uncharacterized recombinant sample. The detection limit of the PCR was 1000 copies/ml, except for 1 subtype C sample (PL3) and 1 CRF02_AG sample (PL8). The detection limit for these samples was 5000 copies/ml. A sequence could be obtained in both directions for most of the samples. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:47 / 53
页数:7
相关论文
共 50 条
  • [31] Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles
    Liao, Wei-Hao
    Huang, Kuo-Jung
    Chang, Yu-Fen
    Wang, Shiu-Mei
    Tseng, Ying-Tzu
    Chiang, Chien-Cheng
    Wang, Jaang-Jiun
    Wang, Chin-Tien
    JOURNAL OF VIROLOGY, 2007, 81 (10) : 5155 - 5165
  • [32] Ribonucleoside Triphosphates as Substrate of Human Immunodeficiency Virus Type 1 Reverse Transcriptase in Human Macrophages
    Kennedy, Edward M.
    Gavegnano, Christina
    Nguyen, Laura
    Slater, Rebecca
    Lucas, Amanda
    Fromentin, Emilie
    Schinazi, Raymond F.
    Kim, Baek
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (50) : 39380 - 39391
  • [33] Recombinant human antibodies against the reverse transcriptase of human immunodeficiency virus type-1
    Herschhorn, A
    Admon, A
    Hizi, A
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2003, 1648 (1-2): : 154 - 163
  • [34] Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations
    Basavapathruni, Aravind
    Vingerhoets, Johan
    de Bethune, Marie-Pierre
    Chung, Raymond
    Bailey, Christopher M.
    Kim, Jiae
    Anderson, Karen S.
    BIOCHEMISTRY, 2006, 45 (23) : 7334 - 7340
  • [35] Properties of human immunodeficiency virus type 1 reverse transcriptase recombination upon infection
    Sakuragi, Sayuri
    Shioda, Tatsuo
    Sakuragi, Jun-ichi
    JOURNAL OF GENERAL VIROLOGY, 2015, 96 : 3382 - 3388
  • [36] Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine
    Lennerstrand, J
    Stammers, DK
    Larder, BA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) : 2144 - 2146
  • [37] Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor
    Pilon, AA
    Lum, JJ
    Sanchez-Dardon, J
    Phenix, BN
    Douglas, R
    Badley, AD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2687 - 2691
  • [38] Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate
    QuinonesMateu, ME
    Soriano, V
    Domingo, E
    MenendezArias, L
    VIROLOGY, 1997, 236 (02) : 364 - 373
  • [39] Inhibition of human immunodeficiency virus type 1 reverse transcriptase by degradation products of ceftazidime
    Baertschi, SW
    Cantrell, AS
    Kuhfeld, MT
    Lorenz, LJ
    Boyd, DB
    Jaskunas, SR
    ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1997, 8 (04): : 353 - 362
  • [40] Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats
    Chang, M
    Sood, VK
    Wilson, GJ
    Kloosterman, DA
    Sanders, PE
    Hauer, MJ
    Fagerness, PE
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (02) : 228 - 242